Effects of ginger on serum glucose, advanced glycation end products, and inflammation in peritoneal dialysis patients

Nutrition

Volumn 31, Issue 5, 2015, Pages 703-707

  Imani, Hossein ^a   Tabibi, Hadi ^a   Najafi, Iraj ^b   Atabak, Shahnaz ^a   Hedayati, Mehdi ^c   Rahmani, Leila ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Shafa Clinic   (Iran)

Author keywords

Advanced glycation end products; Ginger; Glucose; Inflammation; Oxidative stress; Peritoneal dialysis

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; GINGER EXTRACT; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; MALONALDEHYDE; PENTOSIDINE; PLACEBO; SELECTIN; VASCULAR CELL ADHESION MOLECULE 1; ARGININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE BLOOD LEVEL; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

ABSENCE OF SIDE EFFECTS; ADULT; AMINO ACID BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEDICATION COMPLIANCE; OXIDATIVE STRESS; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; DIET THERAPY; DRUG EFFECTS; GINGER; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ZINGIBER OFFICINALE;

ADULT; AGED; ARGININE; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; E-SELECTIN; FEMALE; GINGER; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; MALONDIALDEHYDE; MIDDLE AGED; PERITONEAL DIALYSIS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84933507258     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.11.020     Document Type: Article

References (56)

1. Singh A.K., Brenner B.M. Dialysis in the treatment of renal failure. Harrison's principles of internal medicine 2005, 1663-1667. McGraw-Hill, New York. 16th ed. D.L. Kasper, E. Braunwald, A.S. Fauci, S.L. Hauser, D.L. Longo, J.L. Jameson (Eds.).
2. Jungers P., Khoa T.N., Massy Z.A., Zingraff J., Labrunie M., Descamps-Latscha B., et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patient: a multicentric study in the IIe de france district. Nephrol Dial Transplant 1999, 14:898-902.
3. Wu H.Y., Hung K.Y., Huang T.M., Hu F.C., Peng Y.S., Huang J.W., et al. Safety issues of long-term glucose load in patients on peritoneal dialysis-a 7-year cohort study. PLoS One 2012, 7:E30337.
4. van de Kerkhof J., Schalkwijk C.G., Konings C.J., Cheriex E.C., van der Sande F.M., Scheffer P.G., et al. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients. Nephrol Dial Transplant 2004, 19:910-916.
5. Nishizawa Y., Koyama H., Inaba M. AGEs and cardiovascular diseases in patients with end-stage renal diseases. J Ren Nutr 2012, 22:128-133.
6. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., Nguyen A.T., Gausson V., Mothu N., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005, 45:39-47.
7. Kocak H., Gumuslu S., Ermis C., Mahsereci E., Sahin E., Gocmen A.Y., et al. Oxidative stress and asymmetrical dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients. Am J Nephrol 2008, 28:91-96.
8. Mekki K., Taleb W., Bouzidi N., Kaddous A., Bouchenak M. Effect of hemodialysis and peritoneal dialysis on redox status in chronic renal failure patients: a comparative study. Lipids Health Dis 2010, 9:93.
9. Papagianni A., Kokolina E., Kalovoulos M., Vainas A., Dimitriadis C., Memmos D. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004, 19:1258-1263.
10. Wang A.Y., Lam C.W., Wang M., Woo J., Chan I.H., Lui S.F., et al. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 2005, 45:715-729.
11. Bonomini M., Reale M., Santarelli P., Stuard S., Settefrati N., Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998, 79:399-407.
12. Wang A.Y. Consequences of chronic inflammation in peritoneal dialysis. Semin Nephrol 2011, 31:159-171.
13. Borazan A., Ustün H., Ustundag Y., Aydemir S., Bayraktaroglu T., Sert M., et al. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators Inflamm 2004, 13:201-204.
14. Wu H.Y., Hung K.Y., Hu F.C., Chen Y.M., Chu T.S., Huang J.W., et al. Risk factors for high dialysate glucose use in PD patients-a retrospective 5-year cohort study. Perit Dial Int 2010, 30:448-455.
15. Lai K.N., Tang S.C., Leung J.C. Mediators of inflammation and fibrosis. Perit Dial Int 2007, 27(Suppl 2):S65-S71.
16. Nakamura S., Niwa T. Advanced glycation end-products and peritoneal sclerosis. Semin Nephrol 2004, 24:502-505.
17. Margetts P.J., Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003, 23:530-541.
18. Noh H., Kim J.S., Han K.H., Lee G.T., Song J.S., Chung S.H., et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006, 69:2022-2028.
19. Leong D.J., Choudhury M., Hirsh D.M., Hardin J.A., Cobelli N.J., Sun H.B. Nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritis. Int J Mol Sci 2013, 14:23063-23085.
20. Nicoll R., Henein M.Y. Ginger (Zingiber officinale Roscoe): a hot remedy for cardiovascular disease?. Int J Cardiol 2009, 131:408-409.
21. Arablou T., Aryaeian N., Valizadeh M., Sharifi F., Hosseini A., Djalali M. The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus. Int J Food Sci Nutr 2014, 65:515-520.
22. Mozaffari-Khosravi H., Talaei B., Jalali B.A., Najarzadeh A., Mozayan M.R. The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Complement Ther Med 2014, 22:9-16.
23. Mahluji S., Ostadrahimi A., Mobasseri M., Ebrahimzade Attari V., Payahoo L. Antiinflammatory effects of zingiber officinale in type 2 diabetic patients. Adv Pharm Bull 2013, 3:273-276.
24. Saraswat M., Reddy P.Y., Muthenna P., Reddy G.B. Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications. Br J Nutr 2009, 101:1714-1721.
25. Saraswat M., Suryanarayana P., Reddy P.Y., Patil M.A., Balakrishna N., Reddy G.B. Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. Mol Vis 2010, 16:1525-1537.
26. Song Y., Wei X.B., Ding H., Cheng X.M. Influence of effective part of Zingiber officinal on expression of monocyte chemotactic protein-1 and adhesion molecules. Zhongguo Zhong Yao Za Zhi 2007, 32:2062-2065.
27. Levy A.S., Simon O., Shelly J., Gardener M. 6-Shogaol reduced chronic inflammatory response in the knees of rats treated with complete Freund's adjuvant. BMC Pharmacol 2006, 6:12.
28. Ahmed R.S., Seth V., Banerjee B.D. Influence of dietary ginger (Zingiber officinales Rosc) on antioxidant defense system in rat: comparison with ascorbic acid. Indian J Exp Biol 2000, 38:604-606.
29. Ahmed R.S., Seth V., Pasha S.T., Banerjee B.D. Influence of dietary ginger (Zingiber officinales Rosc) on oxidative stress induced by malathion in rats. Food Chem Toxicol 2000, 38:443-450.
30. Ahmed R.S., Suke S.G., Seth V., Chakraborti A., Tripathi A.K., Banerjee B.D. Protective effects of dietary ginger (Zingiber officinales Rosc.) on lindane-induced oxidative stress in rats. Phytother Res 2008, 22:902-906.
31. Oboh G., Akinyemi A.J., Ademiluyi A.O. Antioxidant and inhibitory effect of red ginger (Zingiber officinale var. Rubra) and white ginger (Zingiber officinale Roscoe) on Fe(2+) induced lipid peroxidation in rat brain invitro. Exp Toxicol Pathol 2012, 64:31-36.
32. Ramudu S.K., Korivi M., Kesireddy N., Chen C.Y., Kuo C.H., Kesireddy S.R. Ginger feeding protects against renal oxidative damage caused by alcohol consumption in rats. J Ren Nutr 2011, 21:263-270.
33. Burkart J.M., Bargman J.M. Adequacy of peritoneal dialysis, including fluid balance. Nolph and Gokal's textbook of peritoneal dialysis 2009, 469-503. Springer, New York. 3rd ed. R. Khanna, R.T. Krediet (Eds.).
34. Blake P.G., Daugirdas J.T. Physiology of peritoneal dialysis. Handbook of dialysis 2001, 281-296. Lippincott Williams & Wilkins, Philadelphia. 3rd ed. J.T. Daugirdas, P.G. Blake, T.S. Ing (Eds.).
35. Oreopoulos D.G., Rao P.S. Assessing peritoneal ultrafiltration, solute transport, and volume status. Handbook of dialysis 2001, 361-372. Lippincott Williams & Wilkins, Philadelphia. 3rd ed. J.T. Daugirdas, P.G. Blake, T.S. Ing (Eds.).
36. Ritz E., Adamczak M., Wiecek A. Carbohydrate metabolism in kidney disease and kidney failure. Nutritional management of renal Disease 2013, 21. Academic Press, Amsterdam. 3rd ed. J.D. Kopple, S.G. Massry, K. Kalantar-Zadeh (Eds.).
37. de Moraes T.P., Fortes P.C., Ribeiro S.C., Riella M.C., Pecoits-Filho R. Comparative analysis of lipid and glucose metabolism biomarkers in non-diabetic hemodialysis and peritoneal dialysis patients. J Bras Nefrol 2011, 33:173-179.
38. Nammi S., Sreemantula S., Roufogalis B.D. Protective effects of ethanolic extract of Zingiber officinale rhizome on the development of metabolic syndrome in high-fat diet-fed rats. Basic Clin Pharmacol Toxicol 2009, 104:366-373.
39. Saravanan G., Ponmurugan P., Deepa M.A., Senthilkumar B. Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet. J Sci Food Agric 2014, 94:2972-2977.
40. Bhandari U., Kanojia R., Pillai K.K. Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats. J Ethnopharmacol 2005, 97:227-230.
41. Al-Amin Z.M., Thomson M., Al-Qattan K.K., Peltonen-Shalaby R., Ali M. Antidiabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. Br J Nutr 2006, 96:660-666.
42. Mahluji S., Attari V.E., Mobasseri M., Payahoo L., Ostadrahimi A., Golzari S.E. Effects of ginger (Zingiber officinale) on plasma glucose level, HbA1 c and insulin sensitivity in type 2 diabetic patients. Int J Food Sci Nutr 2013, 64:682-686.
43. Son M.J., Miura Y., Yagasaki K. Mechanisms for antidiabetic effect of gingerol in cultured cells and obese diabetic model mice. Cytotechnology 2014, (in press).
44. Li Y., Tran V.H., Duke C.C., Roufogalis B.D. Gingerols of Zingiber officinale enhance glucose uptake by increasing cell surface GLUT4 in cultured L6 myotubes. Planta Med 2012, 78:1549-1555.
45. de Strihou C.V., Miyata T. Advanced glycation and advanced oxidation protein products: The effect of peritoneal dialysis. Perit Dial Int 2006, 26:185-187.
46. Miyata T., Horie K., Ueda Y., Fujita Y., Izuhara Y., Hirano H., et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000, 58:425-435.
47. Tauer A., Zhang X., Schaub T.P., Zimmeck T., Niwa T., Passlick-Deetjen J., et al. Formation of advanced glycation end products during CAPD. Am J Kidney Dis 2003, 41(Suppl 1):S57-S60.
48. Miyata T., Saito A., Kurokawa K., van Ypersele de Strihou C. Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity. Nephrol Dial Transplant 2001, 16(Suppl 4):8-11.
49. Miyata T., Kurokawa K., Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000, 11:1744-1752.
50. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
51. Zwolinska D., Grzeszczak W., Szczepanska M., Makulska I., Kilis-Pstrusinska K., Szprynger K. Oxidative stress in children on peritoneal dialysis. Perit Dial Int 2009, 29:171-177.
52. Canaud B., Cristol J., Morena M., Leray-Moragues H., Bosc J., Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 1999, 17:99-106.
53. Lai K.N., Leung J.C. Inflammation in peritoneal dialysis. Nephron Clin Pract 2010, 116:C11-C18.
54. Cho Y., Hawley C.M., Johnson D.W. Clinical causes of inflammation in peritoneal dialysis patients. Int J Nephrol 2014, 2014:909373.
55. Tedgui A. The role of inflammation in atherothrombosis: implications for clinical practice. Vasc Med 2005, 10:45-53.
56. Blankenberg S., Rupprecht H.J., Bickel C., Peetz D., Hafner G., Tiret L., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.